GGTLC1 and metabolic dysfunction-associated steatohepatitis: Further stratification of the indeterminate group patients by other non‐alcoholic steatohepatitis (NASH) clinical predictors, such as abnormal gamma‐glutamyl transpeptidase (GGT) level and presence diabetes mellitus (DM), could further reduce the number of patients who are unlikely to have advanced fibrosis by 52% and 35%, respectively.